David Shaw’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

David Shaw’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-150,000	Closed	-$18K	–	4867
2024 Q4	$18K	Hold	150,000	–	–	﹤0.01%	4249
2024 Q3	$15.6K	Hold	150,000	–	–	﹤0.01%	4357
2024 Q2	$16.7K	Hold	150,000	–	–	﹤0.01%	4282
2024 Q1	$22.5K	Hold	150,000	–	–	﹤0.01%	4114
2023 Q4	$22.5K	Hold	150,000	–	–	﹤0.01%	4064
2023 Q3	$42K	Hold	150,000	–	–	﹤0.01%	3931
2023 Q2	$34.5K	Hold	150,000	–	–	﹤0.01%	3913
2023 Q1	$27K	Buy	+150,000	New	+$23.3K	﹤0.01%	4104

David Shaw's BLACR Position: Q1 2025 in Review

David Shaw sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 150,000 shares — an estimated $18K sold.

David Shaw first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $42K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

David Shaw reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
David Shaw sold 150,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $18K.
David Shaw first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
David Shaw's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $42K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.